A small study shows that a common medication for attention deficit hyperactivity disorder helps children focus by stabilizing how different brain regions communicate with one another. The research, published in Translational Psychiatry, suggests that this brain stabilization is tied directly to better attention and task performance.

The brain constantly balances two opposing states, known as flexibility and stability. Flexibility allows a person to easily switch between different tasks or thoughts. Stability allows a person to ignore distractions and maintain focus on a single goal.

Children with attention deficit hyperactivity disorder, or ADHD, often struggle to maintain this balance. Their brain networks tend to change connections more rapidly. This frequent shifting can manifest as fluctuating attention, impulsive actions, and heightened sensitivity to rewards.

Foundational models of the disorder suggest that these symptoms arise from disruptions in specific neurological circuits. One circuit orients attention through executive control, while another tunes sensitivity to rewards through motivational control. Because these disruptions are widespread across multiple brain systems, looking at how the entire brain communicates is necessary to understand the condition.

Methylphenidate is a common first-line treatment for the disorder. The drug works by blocking the reuptake of dopamine and norepinephrine, which increases the levels of these chemical messengers in the brain. Dopamine and norepinephrine help regulate attention, executive control, and motivation.

The medication effectively reduces symptoms for many children, but up to 30 percent of patients do not experience improvements. A better understanding of how the drug alters brain function on a mechanical level is necessary to explain this variation in effectiveness.

Tehila Nugiel, a psychology researcher at Florida State University, led a team to investigate how methylphenidate influences the balance of brain flexibility and stability. The researchers suspected that the medication might reduce the rapid shifting of brain network connections, driving the brain into a more stable state.

Historically, researchers looked at brain connectivity by averaging activity over several minutes. Newer mathematical methods allow scientists to model how these networks reconfigure on a second-by-second basis. This high-resolution timeline is better suited for capturing the fleeting shifts in focus that characterize the disorder.

To test their hypothesis, the researchers designed a small study involving 31 children between the ages of 8 and 12 who had been diagnosed with ADHD. None of the participants had ever taken stimulant medication before.

Each child visited a laboratory for two separate brain scanning sessions, spaced about a week apart. One hour before entering the magnetic resonance imaging, or MRI, scanner, the children received either a single dose of methylphenidate or a placebo pill. Neither the researchers nor the children knew which pill was given on which day.

Inside the scanner, the children completed a standard test of sustained attention and impulse control. They viewed a series of sports balls on a screen and were instructed to press a button for certain balls and withhold their press for others. This tests a person’s ability to maintain focus without any external incentives.

After the standard version, the children completed a rewarded version of the same task. In this round, they saw feedback after each image, earning pennies for fast, correct responses and for correctly withholding a button press. The rewarded task tests how the brain adapts when performance is tied to an immediate, tangible benefit.

While the children completed these tasks, the researchers recorded their brain activity. Functional MRI tracks blood oxygen changes in the brain, allowing scientists to see which areas are communicating at any given moment. The researchers calculated whole brain flexibility, which measures how frequently different regions of the brain change their functional connections over short timescales.

The researchers also tracked behavioral performance during the scanning sessions. They measured response time variability, which indicates fluctuations in attention, and overall task accuracy.

When the children took methylphenidate, their whole brain flexibility decreased during both tasks. The connection patterns between different brain regions became more stable and persisted for longer periods of time.

This stabilization in the brain matched improvements in behavior. On the medication, the children displayed steadier attention, meaning their response times were less erratic on both tasks. They also achieved higher overall accuracy during the rewarded task.

To understand how the drug affected each child personally, the researchers compared the change in brain activity to the change in test scores. They found a direct relationship between the neural changes and the behavioral improvements. The individuals who experienced the largest decreases in brain flexibility on the medication also showed the greatest improvements in steady attention and accuracy.

These findings provide a biological explanation for how the medication aids cognition. By stabilizing whole brain network dynamics, the drug appears to reduce the neurological noise that often disrupts focus.

There are a few caveats to consider regarding the study design. The experiment involved a single dose of medication given to children who had never taken stimulants. Chronic use of the drug over months or years might alter brain network dynamics differently than an acute dose.

Additionally, the tests performed inside an MRI scanner isolate very specific cognitive processes. These controlled tasks do not perfectly mimic the complicated, distracting environments that children navigate in their daily lives.

The results also highlight notable individual differences among the participants. While the medication stabilized the brain and improved performance for most of the children, a small subset experienced the opposite effect. For these children, the drug increased brain flexibility and led to poorer task performance.

This variation offers a potential clue as to why stimulants fail to reduce symptoms in some individuals. Future research involving larger groups of participants could help scientists predict which patients will benefit from the medication and which might respond better to alternative treatments.

The study, “Methylphenidate stabilizes dynamic brain network organization during tasks probing attention and reward processing in stimulant-naïve children with ADHD,” was authored by Tehila Nugiel, Nicholas D. Fogleman, Monica G. Lyons, Margaret A. Sheridan, and Jessica R. Cohen.

Higher vitamin intake may appear to be associated with fewer depressive symptoms, but most of these relationships disappear once differences in people’s health, socioeconomic circumstances, and behavior are considered, according to a study published in the Journal of Affective Disorders.

Vitamins perform numerous functions that could plausibly affect mental health. Vitamins B6, B9, and B12 contribute to processes involved in producing or regulating chemical messengers in the brain. Vitamins C and E help protect cells from potentially damaging molecules, while vitamin D may influence brain signaling and immune activity.

Previous studies have linked low levels of certain vitamins with depression, raising the possibility that improving nutrition could help prevent or reduce symptoms. However, the evidence has been inconsistent. People with higher vitamin intake may also differ in income, education, physical health, smoking, and other characteristics that independently affect depression risk.

The researchers therefore investigated whether vitamins remained associated with depression after considering these broader differences.

Led by Neil Mistry at Georgia Southern University, the team analyzed data from 26,170 adults (13,294 women, with an average age of 47.6 years) who participated in the National Health and Nutrition Examination Survey between 2005 and 2014.

Participants completed the nine-item Patient Health Questionnaire, a widely used measure producing a depression-symptom score from zero to 27. Of the participants, 75.35% had scores below five. Mild symptoms were recorded in 15.54%, moderate symptoms in 5.60%, moderately severe symptoms in 2.48%, and severe symptoms in 1.02%.

Intake of vitamins A, C, D, and E was estimated by asking participants what they had consumed during the preceding 24 hours. Vitamins B6, B9—also known as folate—and B12 were assessed using blood samples. The researchers also constructed an exploratory score intended to represent overall nutrition.

Initial analyses suggested that higher levels of several vitamins were associated with lower odds of depressive symptoms. Vitamins C, D, and E, for example, were inversely associated with having a score of at least five before other factors were considered. However, these associations were no longer statistically significant after adjustment for age, sex, education, poverty, race, body mass index, health limitations, alcohol intake, and tobacco use.

A similar pattern emerged for more serious symptoms. Apparent relationships involving vitamins A and E weakened after adjustment. Vitamin B12 was not consistently associated with depression, and the overall nutritional score also showed no independent relationship.

Vitamin B6 provided an exception. Higher blood concentrations were associated with lower odds of scoring 15 or above, indicating at least moderately severe symptoms, after the researchers adjusted for other factors. The estimated change associated with each additional unit of B6 was small, however, and should not be interpreted as proof that B6 prevents or treats depression.

As the authors concluded, “These findings do not support strong independent associations between vitamin intake and depression presence or severity after accounting for confounding factors.”

The results instead suggest that some apparent vitamin–depression relationships may reflect wider patterns. Greater depression severity was also associated with lower income, lower educational attainment, poorer self-rated health, physical or sleep limitations, tobacco use, and being unmarried. These circumstances can influence both diet and mental health.

Some limitations are to be noted. For instance, the models did not account for antidepressants, other psychiatric medications, or supplements. Moreover, one day of recalled food intake may poorly represent a person’s normal diet.

The study, “Associations between vitamin intake and depression severity: A cross-sectional analysis of NHANES 2005–2014,” was authored by Neil Mistry, Logan T. Cowan, Hani M. Samawi, Amenah Qotineh, Ousainou Gomez, and Kelly L. Sullivan.